Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1

Open access
Teh, T-C, Nguyen, N-Y, Moujalled, D M, Segal, D, Pomilio, G, Rijal, S, Jabbour, A, Cummins, K, Lackovic, K, Blombery, P, Thompson, E, Ekert, P G, Lessene, G, Glaser, S P, Huang, D C S, Roberts, A W, Guthridge, M A, Wei, A H · 2018 · Leukemia

Abstract

Targeted therapies are frequently combined with standard cytotoxic drugs to enhance clinical response. Targeting the B-cell lymphoma 2 (BCL-2) family of proteins is an attractive option to combat chemoresistance in leukemia. Preclinical and clinical studies indicate modest single-agent activity with selective BCL-2 inhibitors (for example, venetoclax). We show that venetoclax synergizes with cytarabine and idarubicin to increase antileukemic efficacy in a TP53-dependent manner. Although TP53 deficiency impaired sensitivity to combined venetoclax and chemotherapy, higher-dose idarubicin was able to suppress MCL1 and induce cell death independently of TP53. Consistent with an MCL1-specific effect, cell death from high-dose idarubicin was dependent on pro-apoptotic Bak. Combining higher-dose idarubicin with venetoclax was able to partially overcome resistance in Bak-deficient cells. Using inducible vectors and venetoclax to differentially target anti-apoptotic BCL-2 family members, BCL-2 and MCL1 emerged as critical and complementary proteins regulating cell survival in acute myeloid leukemia. Dual targeting of BCL-2 and MCL1, but not either alone, prolonged survival of leukemia-bearing mice. In conclusion, our findings support the further investigation of venetoclax in combination with standard chemotherapy, including intensified doses of idarubicin. Venetoclax should also be investigated in combination with direct inhibitors of MCL1 as a chemotherapy-free approach in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2017.243

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 159

Metadata

Authors
Teh, T.-C., Nguyen, N.-Y., Moujalled, D. M., Segal, D., Pomilio, G., Rijal, S., Jabbour, A., Cummins, K., Lackovic, K., Blombery, P., Thompson, E., Ekert, P. G., Lessene, G., Glaser, S. P., Huang, D. C. S., Roberts, A. W., Guthridge, M. A., & Wei, A. H.
Venue
Leukemia
Published
2017-07-28
Volume
32
Issue
2
Pages
303-312
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2741462465
Cited by
159
References
8
FWCI
13.75
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. https://app.cochat.ai/papers/10.1038/leu.2017.243
The paper
Teh, T.-C., Nguyen, N.-Y., Moujalled, D. M., Segal, D., Pomilio, G., Rijal, S., Jabbour, A., Cummins, K., Lackovic, K., Blombery, P., Thompson, E., Ekert, P. G., Lessene, G., Glaser, S. P., Huang, D. C. S., Roberts, A. W., Guthridge, M. A., & Wei, A. H. (2018). Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia. https://doi.org/10.1038/leu.2017.243

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.